The Contagious Nature of SARS-CoV-2 Omicron Variant and Vaccine Efficacy
Authors:
Open Access
- 21 January 2023
- journal article
- Published by The Running Line in Advancements in Life Sciences
- Vol. 9 (4) , 429-436
Abstract
Background: Since the first COVID-19 outbreak, variants of SARS-CoV-2 have continued to dominate the global population. The repeated waves of emerging variants, each replacing the previous one with a greater rate of transmissibility and mutations, are the primary cause of the global pandemic. Public health concerns dramatically rose when a highly mutated variant (VOC) omicron (B.1.1.529) emerged in late 2021. omicron has more than 50 mutations, and over 30 mutations are in their spike protein that contributes to the virologic characteristics of the variant. Omicron is more contagious than previously reported SARS-CoV-2 strains and can re-infect people who have already contracted other SARS-CoV-2 infections. The variant has acquired a unique immune escape mechanism against monoclonal antibodies and vaccines. Currently, no therapeutic drug or vaccine is specifically available to prevent omicron infection and sublineage emergence. Method: The review was designed to search the recent research and literature and compile the most pertinent data on the virologic characteristics of the variant of concern. Result: The study reviewed and discussed the present prevalence, infectivity, dominance, immune evasion, therapeutic options, vaccine efficacy, and the future prospect of the omicron variant. Conclusion: Omicron variant has become a global public health concern due to the emergence of highly mutated sublineages. Developing variant-specific therapeutic drugs or vaccines is desirable to prevent the spread of these contagious variants globally.Keywords: COVID-19, SARS-CoV-2, Omicron variant, Vaccine efficacy, Immune evasion.Keywords
This publication has 39 references indexed in Scilit:
- Moving targets: COVID-19 vaccine efficacy against Omicron subvariantsMolecular Therapy, 2022
- An L-theanine derivative targets against SARS-CoV-2 and its Delta and Omicron variantsHeliyon, 2022
- Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 OmicronCell, 2022
- Omicron (B.1.1.529 variant of SARS‐CoV‐2); an emerging threat: Current global scenarioJournal of Medical Virology, 2022
- Sequence analysis of the emerging SARS‐CoV‐2 variant Omicron in South AfricaJournal of Medical Virology, 2021
- Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptorBiochemical and Biophysical Research Communications, 2021
- Investigating the aggressiveness of the COVID-19 Omicron variant and suggestions for possible treatment optionsRespiratory Medicine, 2021
- Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodiesJournal of Autoimmunity, 2021
- Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike proteinCell, 2021
- Discovery of human coronaviruses pan-papain-like protease inhibitors using computational approachesJournal of Pharmaceutical Analysis, 2020